Navigation Links
Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
Date:2/28/2008

SAN DIEGO, Feb. 28 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced that patient dosing has commenced in a Phase I study of ANA773, the company's oral TLR7 agonist prodrug, in patients with advanced solid tumors. This first-in-human trial is a safety and tolerability study designed to identify pharmacologically active doses and preliminary antitumor activity as well as to select the dose and schedule for Phase II trials.

The Phase I trial is a multiple, ascending dose study conducted at several sites in the United States. In addition to safety and tolerability, patients will be monitored for pharmacodynamic responses indicative of immunological stimulation. Initially, patients will be dosed every other day. The company also expects to investigate additional schedules during this first clinical trial and anticipates that up to 60 patients will be enrolled in the study.

"The extensive preclinical investigation Anadys has conducted with ANA773 over the last 18 months has taught us much about the pharmacology of orally administered TLR7 agonists, including the importance of schedule in sculpting the profile of immune activation," said James Freddo, M.D., Anadys' Chief Medical Officer. "We believe ANA773 holds promise for the treatment of a range of malignancies and may have utility when combined with targeted agents, therapeutic antibodies and/or chemotherapy. We are excited about having initiated this first clinical study."

Steve Worland, Ph.D., Anadys' President and Chief Executive Officer, said, "This is an important milestone for Anadys. The initiation of this trial marks the resumption of our clinical investigation of oral TLR7 agonists and moves us closer toward our objective of
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
2. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
4. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
7. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
8. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
11. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... With its latest polyacrylonitrile (PAN) ... achieve faster flow rates in comparison to nylon or polyethersulfone (PES). Its ... allow easy liquid flow while trapping particulates as small as 0.2 micron in ...
(Date:6/30/2015)... ... 2015 , ... Matrix Marketing Group, LLC , a leading provider of ... head up its account management department as vice president of client services. Amanda ... account management and delivery expertise to the growing Matrix Marketing Group team in Denver, ...
(Date:6/30/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... on the development of autologous cell therapies, announced today ... clinical trial of RCT-01, being tested for the ... enrolled and their tissue biopsy sent for processing ... of non-bulbar dermal sheath (NBDS) cells isolated from ...
(Date:6/30/2015)... ... June 30, 2015 , ... Smarter Alloys today announced a ... archwire that allows orthodontists to simultaneously apply different forces to different teeth. The ... “We’re thrilled about taking SmartArch one step closer to commercial availability for orthodontists ...
Breaking Biology Technology:New Nanofiber Membrane Provides Fast, Efficient Filtration 2Matrix Marketing Group Expands Client Services Team 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2
... The long-awaited speaking faculty for the September Pharma ... the conference website reports Mark Alexay, President of ... is comprised of 100 speakers from pharmaceutical companies ... in the pipeline. The speaker list may be ...
... of Avastin Will Take Market Share Away from ... New Report from Decision ResourcesWALTHAM, Mass., March 10 ... research and advisory firms for pharmaceutical and healthcare ... in the age-related macular degeneration (AMD) market through ...
... March 10 Christine Lawless, MD, has ... an ACCME-accredited provider of continuing medical education (CME), beginning ... leading authorities in sports medicine cardiology, Dr. Lawless recently ... University Medical Center, where she was Associate Professor ...
Cached Biology Technology:Pharma ChemOutsourcing Unveils 100 Pharma & Biotech Speaker Faculty for 2009 Conference September 14-16 in Long Branch, NJ 2Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe 2Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe 3Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise 2
(Date:6/8/2015)... -- Trovagene, Inc. (NASDAQ: TROV ), a developer of cell-free ... Cancer Monitoring SM platform will be presented at the ... San Diego, CA on June 11-12 , ... Genomics and Cancer Therapy in Salt Lake ... "We continue to advance our clinical programs and present data ...
(Date:6/5/2015)... 5, 2015  Intrexon Corporation ("Intrexon") (NYSE: XON ... it has determined the final distribution ratio relating to ... shares of ZIOPHARM Oncology, Inc. ("ZIOPHARM") (NASDAQ: ZIOP ... the distribution date, as a pro rata dividend on ... purchase shares of Intrexon common stock ("Warrants"), outstanding on ...
(Date:6/1/2015)... June 1, 2015 According to ... Sensing Market by Technology (Touch-based & Touchless), Application (Consumer ... & by Geography - Global Forecast to 2020", published ... is expected to reach $23.55 Billion by 2020, at ... Browse 83 market data T ables ...
Breaking Biology News(10 mins):Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 2Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 3Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 4Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4
... 2011 The risk of deadly hantavirus outbreaks in people ... images to monitor surges in vegetation that boost mouse populations, ... forecast outbreaks of other rodent-borne illnesses worldwide. "It,s a ... out and trap animals all the time," says Denise Dearing, ...
... analysis of sulfur emissions appearing in the journal ... for a decade, worldwide emissions rose again in 2000 ... economy. An accurate read on sulfur emissions will help ... day effects on the atmosphere, health and the environment. ...
... MADISON Recalculating the global use of phosphorous, a fertilizer ... the world,s stocks may soon be in short supply and ... cause of the pollution of lakes, rivers and streams. ... Environmental Research Letters , Stephen Carpenter of the University of ...
Cached Biology News:Monitoring killer mice from space 2Monitoring killer mice from space 3Monitoring killer mice from space 4Monitoring killer mice from space 5Worldwide sulfur emissions rose between 2000-2005, after decade of decline 2Worldwide sulfur emissions rose between 2000-2005, after decade of decline 3Worldwide sulfur emissions rose between 2000-2005, after decade of decline 4World phosphorous use crosses critical threshold 2World phosphorous use crosses critical threshold 3
Mouse monoclonal [AZ24] to Polo like kinase ( Abpromise for all tested applications)....
... Applied Science, which pioneered the blending of ... Fidelity and Expand Long Template PCR Systems, ... System the first product of a ... new blend combines Taq DNA Polymerase with ...
... RY 13 5'G AATTC3' 3'CTTAA G5' Inactivation Conditions: ... ethanol precipitation. Storage Conditions: 10mM Tris-HCl (pH 7.5), ... X-100, 0.01% BSA, 50% glycerol. Shipping and Storage: ... Definition: One unit is defined as the amount ...
... Source: Bacillus globigii 5'GCCNNNN NGGC3' 3'CGGN NNNNCCG5' ... 15 min or phenol treatment followed by ... 8.0), 200mM KCl, 0.1mM EDTA, 1.0mM DTT, ... Shipped on dry ice. Store at -20C. ...
Biology Products: